1310383-45-9

Basic information

• Product Name: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL[1,3,2]DIOXABOROLAN-2-YL)PHENOXYMETHYL]PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL[1,3,2]DIOXABOROLAN-2-YL)PHENOXYMETHYL]PIPERIDINE-1-CARBOXYLATE;tert-Butyl 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxa-borolan-2-yl)phenoxymethyl]piperidine-1-carbo;QSHLBDDCJBXAMS-UHFFFAOYSA-N
• CAS NO: 1310383-45-9
• Molecular Formula: C23H36BNO5
• Molecular Weight: 417.34664
• EINECS: -0
• Mol File: 1310383-45-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 511.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• PKA: -1.72±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL[1,3,2]DIOXABOROLAN-2-YL)PHENOXYMETHYL]PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL[1,3,2]DIOXABOROLAN-2-YL)PHENOXYMETHYL]PIPERIDINE-1-CARBOXYLATE(1310383-45-9)
• EPA Substance Registry System: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL[1,3,2]DIOXABOROLAN-2-YL)PHENOXYMETHYL]PIPERIDINE-1-CARBOXYLATE(1310383-45-9)

Safety Data

• Hazardous Substances Data: 1310383-45-9(Hazardous Substances Data)

Upstream product

• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Relevant articles and documents

3-HYDROXY-N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)PYRROLIDINE-1-CARBOXAMIDE DERIVATIVES

The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions compris

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.